Form 4: Tenaya Therapeutics SVP Sells Shares for Tax Obligations

Tenaya Therapeutics SVP of Finance Tomohiro Higa sold 1,485 shares of common stock to satisfy tax withholding requirements related to RSU vesting.

Summary

• Tomohiro Higa, SVP of Finance at Tenaya Therapeutics, Inc., sold 1,485 shares of common stock.
• The transaction occurred on May 18, 2026, at a price of $0.7932 per share.
• The sale was executed to cover tax withholding obligations resulting from the vesting of restricted stock units (RSUs) granted on August 15, 2024.
• Following this transaction, the reporting person maintains beneficial ownership of 118,267 shares, which includes 67,938 shares underlying unvested RSUs.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was purely administrative to satisfy tax obligations and does not reflect a change in the executive's outlook on the company.

Positives

• The sale was a mandatory 'sell-to-cover' transaction to satisfy tax obligations rather than a discretionary divestment of equity.

Negatives

• The transaction reflects a reduction in direct share ownership by a member of the senior management team.

Risks

• Continued reliance on equity-based compensation for key personnel may lead to periodic selling pressure as RSUs vest.

Future Outlook

No forward-looking guidance regarding company performance or strategy was provided in this filing.

Industry Context

StockSavvy.ai notes that 'sell-to-cover' transactions are standard practice in the biotechnology sector, where equity compensation is a significant component of executive remuneration, and do not typically signal a change in management sentiment regarding company prospects.

Comparison to Industry Standards

• The transaction is consistent with standard corporate governance practices for managing tax liabilities associated with RSU vesting in publicly traded biotech firms.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was a routine tax-related sale.

Next Steps

• Future vesting of remaining 67,938 restricted stock units subject to continued employment.

Key Dates

Keywords

Tenaya Therapeutics, TNYA, Insider Trading, Form 4, Biotech, Equity Compensation